Exchange: NASDAQ·Updated 07:55 PM EDT

ETON News

News
all
press releases
PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M
A substantial insider activity was disclosed on August 31, as V, Board Member at Eton Pharmaceuticals (NASDAQ:ETON), reported the exercise of a large sell of company stock options. What Happened: A Form 4 filing withread more...
Benzinga
More News
SEAN BRYNJELSEN Executes Sell Order: Offloads $6.09M In Eton Pharmaceuticals Stock
On August 20, a recent SEC filing unveiled that SEAN BRYNJELSEN, President & CEO at Eton Pharmaceuticals (NASDAQ:ETON) made an insider sell. What Happened: According to a Form 4 filing with the U.S. Securities andread more...
Benzinga
Why Eton Pharmaceuticals Is Top of the Class Today
Key PointsEton Pharmaceuticals beat on both top and bottom lines last night...
Nasdaq News: Markets
This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
Eton expects full-year 2026 revenue to exceed $145 million, up from its previous forecast of more than $120 million.
Stocktwits
Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected earnings. Other big gains include ETON, VALN, IMXI.read more...
Benzinga
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.read more...
Benzinga
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of +218.18% and +38.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of +24.64% and +9.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock?
Craig-Hallum on Tuesday lifted its price target on ETON to $62 from $40 and kept a Buy rating.
Stocktwits
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks

Advertisement|Remove ads.